NICE Rejects New MS Pill as too Expensive

Amanda Kirk's life improved with fingolimod, a drug for MS, but NICE deemed it not cost-effective, impacting many patients. The MS Society opposes this decision, fearing it will leave thousands without necessary treatment. Amanda's treatment is secure until December, after which private payment may be required.

What new insight or understanding did you gain from this video?